Therapeutic Effects of Glucagon-like Peptide-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: A Systematic Review.

Mahoon D, Kellany F, Khan I, Khan S, Butler AE

International journal of molecular sciences22 Jun 2026

PMID42353331PMCIDPMC13299499DOI10.3390/ijms27125618PepBankPUB-42353331

Summary

Non-alcoholic fatty liver disease (NAFLD), now increasingly termed metabolic dysfunction-associated steatotic liver disease (MASLD), is a growing cause of chronic liver disease with limited treatment options. Glucagon-like peptide-1 (GLP-1) receptor agonists, approved for type 2 diabetes and obesity, possess metabolic effects that may render them suitable for treating NAFLD and metabolic dysfunction-associated steatohepatitis (MASH). To evaluate the therapeutic effects of GLP-1 receptor agonists in adults with NAFLD, non-alcoholic steatohepatitis (NASH), MASLD, or MASH. PubMed, Scopus, Embase, and the Cochrane Library were systematically searched using keywords related to NAFLD and GLP-1 receptor agonists. Given heterogeneity in populations, designs, and outcomes, findings were synthesized narratively. The review is registered with PROSPERO (CRD420261337353). Twelve studies met the inclusion criteria. The most consistent outcome was a reduction in hepatic fat, seen with semaglutide, liraglutide, dulaglutide, and beinaglutide. Improvements in liver enzymes, particularly alanine aminotransferase, were less consistent and best regarded as supportive rather than definitive evidence of histological improvement. Histological benefits were strongest for steatohepatitis resolution in non-cirrhotic MASH. Fibrosis findings were mixed, with the greatest benefit in F2-F3 MASH and limited improvement in established cirrhosis. GLP-1 receptor agonists were generally well tolerated, with gastrointestinal symptoms the most common adverse effects. GLP-1 receptor agonists show promising liver-related benefits in NAFLD and MASH, particularly in obesity, type 2 diabetes, or earlier-stage disease. Their effects on advanced fibrosis and long-term outcomes remain uncertain, warranting larger, longer-term studies.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study16

2 results from studies that gave the peptide. 2 results from people.

01HumanSystematic reviewEfficacy outcome
In a searched systematic review of adults with NAFLD, NASH, MASLD or MASH, semaglutide was associated with reduced hepatic fat.
In plain wordsIn a systematic review of adults with fatty liver disease, semaglutide was linked to lower liver fat.
Peptide
Semaglutide
Outcome
DecreaseHepatic fat
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Source sentences
Summary
The most consistent outcome was a reduction in hepatic fat, seen with semaglutide, liraglutide, dulaglutide, and beinaglutide.
3 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the therapeutic effects of GLP-1 receptor agonists in adults with NAFLD, non-alcoholic steatohepatitis (NASH), MASLD, or MASH.
Summary · context
PubMed, Scopus, Embase, and the Cochrane Library were systematically searched using keywords related to NAFLD and GLP-1 receptor agonists.
Summary · context
Given heterogeneity in populations, designs, and outcomes, findings were synthesized narratively.
Show in the study text Report a problemFND-4235333101
02HumanSystematic reviewEfficacy outcome
In a searched systematic review of adults with NAFLD, NASH, MASLD or MASH, liraglutide was associated with reduced hepatic fat.
In plain wordsIn a systematic review of adults with fatty liver disease, liraglutide was linked to lower liver fat.
Peptide
Liraglutide
Outcome
DecreaseHepatic fat
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Source sentences
Summary
The most consistent outcome was a reduction in hepatic fat, seen with semaglutide, liraglutide, dulaglutide, and beinaglutide.
3 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the therapeutic effects of GLP-1 receptor agonists in adults with NAFLD, non-alcoholic steatohepatitis (NASH), MASLD, or MASH.
Summary · context
PubMed, Scopus, Embase, and the Cochrane Library were systematically searched using keywords related to NAFLD and GLP-1 receptor agonists.
Summary · context
Given heterogeneity in populations, designs, and outcomes, findings were synthesized narratively.
Show in the study text Report a problemFND-4235333102

Studies that did not test the peptide alone14

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

03HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with NAFLD, NASH, MASLD or MASH, class-level GLP-1 findings including semaglutide showed less-consistent liver-enzyme improvements, particularly ALT, supportive rather than definitive evidence of histological improvement.
In plain wordsIn adults with fatty liver disease, pooled GLP-1 drugs including semaglutide showed less-consistent ALT improvement; this did not establish histological improvement.
Peptide
Semaglutide
Outcome
Direction not reportedAlanine aminotransferase improvement
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
Improvements in liver enzymes, particularly alanine aminotransferase, were less consistent and best regarded as supportive rather than definitive evidence of histological improvement.
4 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the therapeutic effects of GLP-1 receptor agonists in adults with NAFLD, non-alcoholic steatohepatitis (NASH), MASLD, or MASH.
Summary · context
PubMed, Scopus, Embase, and the Cochrane Library were systematically searched using keywords related to NAFLD and GLP-1 receptor agonists.
Summary · context
Given heterogeneity in populations, designs, and outcomes, findings were synthesized narratively.
Summary · context
The most consistent outcome was a reduction in hepatic fat, seen with semaglutide, liraglutide, dulaglutide, and beinaglutide.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4235333103
04HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with NAFLD, NASH, MASLD or MASH, class-level GLP-1 findings including liraglutide showed less-consistent liver-enzyme improvements, particularly ALT, supportive rather than definitive evidence of histological improvement.
In plain wordsIn adults with fatty liver disease, pooled GLP-1 drugs including liraglutide showed less-consistent ALT improvement; this did not establish histological improvement.
Peptide
Liraglutide
Outcome
Direction not reportedAlanine aminotransferase improvement
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
Improvements in liver enzymes, particularly alanine aminotransferase, were less consistent and best regarded as supportive rather than definitive evidence of histological improvement.
4 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the therapeutic effects of GLP-1 receptor agonists in adults with NAFLD, non-alcoholic steatohepatitis (NASH), MASLD, or MASH.
Summary · context
PubMed, Scopus, Embase, and the Cochrane Library were systematically searched using keywords related to NAFLD and GLP-1 receptor agonists.
Summary · context
Given heterogeneity in populations, designs, and outcomes, findings were synthesized narratively.
Summary · context
The most consistent outcome was a reduction in hepatic fat, seen with semaglutide, liraglutide, dulaglutide, and beinaglutide.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4235333104
05HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In the adult fatty-liver systematic review, class-level GLP-1 findings including semaglutide showed strongest histological benefit for steatohepatitis resolution in non-cirrhotic MASH.
In plain wordsIn adults with non-cirrhotic MASH, pooled GLP-1 findings including semaglutide showed strongest histological benefit for steatohepatitis resolution.
Peptide
Semaglutide
Outcome
Direction not reportedSteatohepatitis resolution
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
Histological benefits were strongest for steatohepatitis resolution in non-cirrhotic MASH.
4 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the therapeutic effects of GLP-1 receptor agonists in adults with NAFLD, non-alcoholic steatohepatitis (NASH), MASLD, or MASH.
Summary · context
PubMed, Scopus, Embase, and the Cochrane Library were systematically searched using keywords related to NAFLD and GLP-1 receptor agonists.
Summary · context
Given heterogeneity in populations, designs, and outcomes, findings were synthesized narratively.
Summary · context
The most consistent outcome was a reduction in hepatic fat, seen with semaglutide, liraglutide, dulaglutide, and beinaglutide.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4235333105
06HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In the adult fatty-liver systematic review, class-level GLP-1 findings including liraglutide showed strongest histological benefit for steatohepatitis resolution in non-cirrhotic MASH.
In plain wordsIn adults with non-cirrhotic MASH, pooled GLP-1 findings including liraglutide showed strongest histological benefit for steatohepatitis resolution.
Peptide
Liraglutide
Outcome
Direction not reportedSteatohepatitis resolution
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
Histological benefits were strongest for steatohepatitis resolution in non-cirrhotic MASH.
4 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the therapeutic effects of GLP-1 receptor agonists in adults with NAFLD, non-alcoholic steatohepatitis (NASH), MASLD, or MASH.
Summary · context
PubMed, Scopus, Embase, and the Cochrane Library were systematically searched using keywords related to NAFLD and GLP-1 receptor agonists.
Summary · context
Given heterogeneity in populations, designs, and outcomes, findings were synthesized narratively.
Summary · context
The most consistent outcome was a reduction in hepatic fat, seen with semaglutide, liraglutide, dulaglutide, and beinaglutide.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4235333106
07HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with NAFLD, NASH, MASLD or MASH, class-level GLP-1 findings including semaglutide showed mixed fibrosis results.
In plain wordsIn adults with fatty liver disease, pooled GLP-1 findings including semaglutide showed mixed fibrosis results.
Peptide
Semaglutide
Outcome
MixedFibrosis
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
Fibrosis findings were mixed, with the greatest benefit in F2-F3 MASH and limited improvement in established cirrhosis.
4 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the therapeutic effects of GLP-1 receptor agonists in adults with NAFLD, non-alcoholic steatohepatitis (NASH), MASLD, or MASH.
Summary · context
PubMed, Scopus, Embase, and the Cochrane Library were systematically searched using keywords related to NAFLD and GLP-1 receptor agonists.
Summary · context
Given heterogeneity in populations, designs, and outcomes, findings were synthesized narratively.
Summary · context
The most consistent outcome was a reduction in hepatic fat, seen with semaglutide, liraglutide, dulaglutide, and beinaglutide.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4235333107
08HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with NAFLD, NASH, MASLD or MASH, class-level GLP-1 findings including liraglutide showed mixed fibrosis results.
In plain wordsIn adults with fatty liver disease, pooled GLP-1 findings including liraglutide showed mixed fibrosis results.
Peptide
Liraglutide
Outcome
MixedFibrosis
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
Fibrosis findings were mixed, with the greatest benefit in F2-F3 MASH and limited improvement in established cirrhosis.
4 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the therapeutic effects of GLP-1 receptor agonists in adults with NAFLD, non-alcoholic steatohepatitis (NASH), MASLD, or MASH.
Summary · context
PubMed, Scopus, Embase, and the Cochrane Library were systematically searched using keywords related to NAFLD and GLP-1 receptor agonists.
Summary · context
Given heterogeneity in populations, designs, and outcomes, findings were synthesized narratively.
Summary · context
The most consistent outcome was a reduction in hepatic fat, seen with semaglutide, liraglutide, dulaglutide, and beinaglutide.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4235333108
09HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In adults with NAFLD, NASH, MASLD or MASH, gastrointestinal symptoms were the most common adverse effects across GLP-1 drugs including semaglutide.
In plain wordsIn adults with fatty liver disease, stomach and bowel symptoms were the most common side effects across GLP-1 drugs including semaglutide.
Peptide
Semaglutide
Outcome
Not applicableGastrointestinal symptoms
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
GLP-1 receptor agonists were generally well tolerated, with gastrointestinal symptoms the most common adverse effects.
4 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the therapeutic effects of GLP-1 receptor agonists in adults with NAFLD, non-alcoholic steatohepatitis (NASH), MASLD, or MASH.
Summary · context
PubMed, Scopus, Embase, and the Cochrane Library were systematically searched using keywords related to NAFLD and GLP-1 receptor agonists.
Summary · context
Given heterogeneity in populations, designs, and outcomes, findings were synthesized narratively.
Summary · context
The most consistent outcome was a reduction in hepatic fat, seen with semaglutide, liraglutide, dulaglutide, and beinaglutide.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4235333109
10HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In adults with NAFLD, NASH, MASLD or MASH, gastrointestinal symptoms were the most common adverse effects across GLP-1 drugs including liraglutide.
In plain wordsIn adults with fatty liver disease, stomach and bowel symptoms were the most common side effects across GLP-1 drugs including liraglutide.
Peptide
Liraglutide
Outcome
Not applicableGastrointestinal symptoms
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
GLP-1 receptor agonists were generally well tolerated, with gastrointestinal symptoms the most common adverse effects.
4 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the therapeutic effects of GLP-1 receptor agonists in adults with NAFLD, non-alcoholic steatohepatitis (NASH), MASLD, or MASH.
Summary · context
PubMed, Scopus, Embase, and the Cochrane Library were systematically searched using keywords related to NAFLD and GLP-1 receptor agonists.
Summary · context
Given heterogeneity in populations, designs, and outcomes, findings were synthesized narratively.
Summary · context
The most consistent outcome was a reduction in hepatic fat, seen with semaglutide, liraglutide, dulaglutide, and beinaglutide.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4235333110
11HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In the systematic review of adults with F2-F3 MASH, class-level GLP-1 findings including semaglutide showed the greatest fibrosis benefit.
In plain wordsIn adults with F2-F3 MASH, across GLP-1 drugs including semaglutide, fibrosis benefit was greatest.
Peptide
Semaglutide
Outcome
Direction not reportedFibrosis benefit in F2-F3 MASH
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
Fibrosis findings were mixed, with the greatest benefit in F2-F3 MASH and limited improvement in established cirrhosis.
4 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the therapeutic effects of GLP-1 receptor agonists in adults with NAFLD, non-alcoholic steatohepatitis (NASH), MASLD, or MASH.
Summary · context
PubMed, Scopus, Embase, and the Cochrane Library were systematically searched using keywords related to NAFLD and GLP-1 receptor agonists.
Summary · context
Given heterogeneity in populations, designs, and outcomes, findings were synthesized narratively.
Summary · context
The most consistent outcome was a reduction in hepatic fat, seen with semaglutide, liraglutide, dulaglutide, and beinaglutide.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4235333111
12HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In the systematic review of adults with established cirrhosis, class-level GLP-1 findings including semaglutide showed limited fibrosis improvement.
In plain wordsIn adults with established cirrhosis, across GLP-1 drugs including semaglutide, fibrosis improvement was limited.
Peptide
Semaglutide
Outcome
Direction not reportedFibrosis improvement in established cirrhosis
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
Fibrosis findings were mixed, with the greatest benefit in F2-F3 MASH and limited improvement in established cirrhosis.
4 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the therapeutic effects of GLP-1 receptor agonists in adults with NAFLD, non-alcoholic steatohepatitis (NASH), MASLD, or MASH.
Summary · context
PubMed, Scopus, Embase, and the Cochrane Library were systematically searched using keywords related to NAFLD and GLP-1 receptor agonists.
Summary · context
Given heterogeneity in populations, designs, and outcomes, findings were synthesized narratively.
Summary · context
The most consistent outcome was a reduction in hepatic fat, seen with semaglutide, liraglutide, dulaglutide, and beinaglutide.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4235333112
13HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In the systematic review of adults with NAFLD, NASH, MASLD or MASH, class-level GLP-1 findings including semaglutide were generally well tolerated.
In plain wordsIn adults with fatty liver disease, across GLP-1 drugs including semaglutide, treatment was generally well tolerated.
Peptide
Semaglutide
Outcome
Not applicableOverall tolerability
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Source sentences
Summary
GLP-1 receptor agonists were generally well tolerated, with gastrointestinal symptoms the most common adverse effects.
4 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the therapeutic effects of GLP-1 receptor agonists in adults with NAFLD, non-alcoholic steatohepatitis (NASH), MASLD, or MASH.
Summary · context
PubMed, Scopus, Embase, and the Cochrane Library were systematically searched using keywords related to NAFLD and GLP-1 receptor agonists.
Summary · context
Given heterogeneity in populations, designs, and outcomes, findings were synthesized narratively.
Summary · context
The most consistent outcome was a reduction in hepatic fat, seen with semaglutide, liraglutide, dulaglutide, and beinaglutide.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4235333113
14HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In the systematic review of adults with F2-F3 MASH, class-level GLP-1 findings including liraglutide showed the greatest fibrosis benefit.
In plain wordsIn adults with F2-F3 MASH, across GLP-1 drugs including liraglutide, fibrosis benefit was greatest.
Peptide
Liraglutide
Outcome
Direction not reportedFibrosis benefit in F2-F3 MASH
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
Fibrosis findings were mixed, with the greatest benefit in F2-F3 MASH and limited improvement in established cirrhosis.
4 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the therapeutic effects of GLP-1 receptor agonists in adults with NAFLD, non-alcoholic steatohepatitis (NASH), MASLD, or MASH.
Summary · context
PubMed, Scopus, Embase, and the Cochrane Library were systematically searched using keywords related to NAFLD and GLP-1 receptor agonists.
Summary · context
Given heterogeneity in populations, designs, and outcomes, findings were synthesized narratively.
Summary · context
The most consistent outcome was a reduction in hepatic fat, seen with semaglutide, liraglutide, dulaglutide, and beinaglutide.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4235333114
15HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In the systematic review of adults with established cirrhosis, class-level GLP-1 findings including liraglutide showed limited fibrosis improvement.
In plain wordsIn adults with established cirrhosis, across GLP-1 drugs including liraglutide, fibrosis improvement was limited.
Peptide
Liraglutide
Outcome
Direction not reportedFibrosis improvement in established cirrhosis
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
Fibrosis findings were mixed, with the greatest benefit in F2-F3 MASH and limited improvement in established cirrhosis.
4 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the therapeutic effects of GLP-1 receptor agonists in adults with NAFLD, non-alcoholic steatohepatitis (NASH), MASLD, or MASH.
Summary · context
PubMed, Scopus, Embase, and the Cochrane Library were systematically searched using keywords related to NAFLD and GLP-1 receptor agonists.
Summary · context
Given heterogeneity in populations, designs, and outcomes, findings were synthesized narratively.
Summary · context
The most consistent outcome was a reduction in hepatic fat, seen with semaglutide, liraglutide, dulaglutide, and beinaglutide.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4235333115
16HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In the systematic review of adults with NAFLD, NASH, MASLD or MASH, class-level GLP-1 findings including liraglutide were generally well tolerated.
In plain wordsIn adults with fatty liver disease, across GLP-1 drugs including liraglutide, treatment was generally well tolerated.
Peptide
Liraglutide
Outcome
Not applicableOverall tolerability
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Source sentences
Summary
GLP-1 receptor agonists were generally well tolerated, with gastrointestinal symptoms the most common adverse effects.
4 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the therapeutic effects of GLP-1 receptor agonists in adults with NAFLD, non-alcoholic steatohepatitis (NASH), MASLD, or MASH.
Summary · context
PubMed, Scopus, Embase, and the Cochrane Library were systematically searched using keywords related to NAFLD and GLP-1 receptor agonists.
Summary · context
Given heterogeneity in populations, designs, and outcomes, findings were synthesized narratively.
Summary · context
The most consistent outcome was a reduction in hepatic fat, seen with semaglutide, liraglutide, dulaglutide, and beinaglutide.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4235333116

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Therapeutic Effects of Glucagon-like Peptide-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: A Systematic Review.

Summary

Results from this study16

Studies that did not test the peptide alone14

Version history

Subjects

Publication types

MeSH terms

Keywords